Rejuvenate Biomed Closes $15.7M Series B Round

Rejuvenate Biomed, a clinical-stage company focused on age-related diseases, has secured $15,700,000 in a recent funding round. Founded in 2017, the privately-held company is dedicated to the discovery and development of therapeutics aimed at preventing or delaying the onset of multiple age-related conditions. This significant capital infusion marks a key milestone for the firm as it progresses its research and development initiatives. The company operates as a platform and pipeline entity, utilizing proprietary technologies to identify safe compounds that influence the aging process. This approach allows Rejuvenate Biomed to discover novel combination drugs with the potential to improve healthspan. Its methodology involves confirming prediction data through rigorous preclinical models and subsequent clinical studies. Rejuvenate Biomed’s lead drug candidate, RJx-01, is currently undergoing Phase 1b clinical trials for the treatment of sarcopenia, a progressive age-associated loss of muscle function and mass. This funding round provides crucial capital to further Rejuvenate Biomed's clinical programs and advance its research pipeline. The $15,700,000 investment is expected to primarily support the continued development of RJx-01 through its clinical phases. Additionally, the capital will strengthen the company's platform for discovering and developing other potential therapeutics addressing age-related diseases. The successful raise underscores investor confidence in the company's scientific approach and its potential to address significant unmet medical needs. With this new funding, Rejuvenate Biomed is well-positioned to accelerate its mission of developing innovative treatments that help people maintain health throughout their lives. The company intends to continue expanding its understanding of the aging process and translating that knowledge into effective pharmaceutical interventions, aiming to make a substantial impact on age-related health challenges.